NIPH Clinical Trials Search

Teneligliptin effects on DPP-4 and glucagon concentrations in the serum during a meal test in patients with type 2 diabetes

Basic Information

Recruitment status	Recruiting
Health condition(s) or Problem(s) studied	Type 2 diabetes
Date of first enrollment	2013/11/01
Target sample size	20
Countries of recruitment	Japan
Study type	Interventional
Intervention(s)	Teneligliptin 20 mg/day

Outcome(s)

Primary Outcome	Postprandial serum soluble CD26/DPP-4 levels, DPP-4 activity, and plasma glucose
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum	20years-old
Age maximum	Not applicable
Gender	Male and Female
Include criteria
Exclude criteria	1.Patients who have type 1 diabetes and/or secondary diabetes (Cushing syndrome or acromegaly). 2.Contraindication for DPP-4 inhibitors 3.Patients who have heart failure (NYHA category 3-4) 4.Patients who are prone to QT prolongation. 5 Alcohol intake excess. 6.Patients who are pregnant or may be pregnant 7.History of myocardial infarction 8.Patients who have received GLP-1 receptor agonists